Fig. 1

Patients with distant relapse exhibit lower CDH1 protein levels and higher Prosigna™ score than controls. a, b ROR score (a) and risk of distant recurrence at 10 years (b) assessed by Prosigna™ according to the recurrence status (N = 99, 49 controls, 50 cases). Horizontal dashed lines split patients according to the risk category, as defined by the Prosigna™ test as low, intermediate or high risk. p values are from Wilcoxon tests. c Representative views of CDH1 (E-cadherin) immunostaining in controls (left) and cases (right) (scale bar = 50 μm). d Boxplot showing CDH1 H score according to the recurrence status and the molecular subtype (N = 92, 44 controls, 48 cases). H score were given as a function of percentage of stained cancer cells multiplied by its respective staining intensity (ranging from 0 to 3). e, f Correlations between CDH1 H score and mitotic index (count of mitotic figures in 10 consecutive high-magnification fields) (e) (N = 92, 44 controls, 48 cases) or between CDH1 H score and ROR score (f) (N = 87, 42 controls, 45 cases). p values are from Spearman’s correlation tests. Lobular carcinomas (N = 12, 8 controls, 4 cases) were excluded from all CDH1 analyses due to their constitutive loss of CDH1 expression. The color code for boxplots and correlation plots is indicated below the figure. It depicts the BC subtype assessed by Prosigna™ test. Luminal A BC are in light blue (controls, N = 37) and light red (cases, N = 27). Luminal B BC are in dark blue (controls, N = 11) and dark red (cases, N = 19). HER2-enriched BC are in light green (controls, N = 2) and dark green (cases, N = 2). The basal-like BC is in yellow. BC without result for Prosigna™ test are in gray (2 controls and 3 cases)